Details of the Drug

General Information of Drug (ID: DM3M9OY)

Drug Name
Anti-CD19/20-CAR vector-transduced T cells
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Clinical trial [1]
B-cell chronic lymphocytic leukaemia 2A82.00 Clinical trial [1]
Chronic lymphocytic leukaemia 2A82.0 Clinical trial [1]
Diffuse large B-cell lymphoma 2A81 Clinical trial [1]
Follicular lymphoma 2A80 Clinical trial [1]
Mantle cell lymphoma 2A85.5 Clinical trial [1]
Prolymphocytic leukaemia 2A82.1 Clinical trial [1]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0NL9N
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20